These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 29176400)

  • 1. Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population.
    Chong HY; Lim YH; Prawjaeng J; Tassaneeyakul W; Mohamed Z; Chaiyakunapruk N
    Pharmacogenet Genomics; 2018 Feb; 28(2):56-67. PubMed ID: 29176400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population.
    Saokaew S; Tassaneeyakul W; Maenthaisong R; Chaiyakunapruk N
    PLoS One; 2014; 9(4):e94294. PubMed ID: 24732692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of
    Duong KN; Nguyen DV; Chaiyakunapruk N; Nelson RE; Malone DC
    Pharmacogenomics; 2023 Aug; 24(13):713-724. PubMed ID: 37706247
    [No Abstract]   [Full Text] [Related]  

  • 4. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
    Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
    Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.
    Dong D; Tan-Koi WC; Teng GG; Finkelstein E; Sung C
    Pharmacogenomics; 2015 Nov; 16(16):1781-93. PubMed ID: 26554739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States.
    Jutkowitz E; Dubreuil M; Lu N; Kuntz KM; Choi HK
    Semin Arthritis Rheum; 2017 Apr; 46(5):594-600. PubMed ID: 27916277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis.
    Somkrua R; Eickman EE; Saokaew S; Lohitnavy M; Chaiyakunapruk N
    BMC Med Genet; 2011 Sep; 12():118. PubMed ID: 21906289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis.
    Yu KH; Yu CY; Fang YF
    Int J Rheum Dis; 2017 Sep; 20(9):1057-1071. PubMed ID: 28857441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
    Yeo SI
    Int J Rheum Dis; 2013 Jun; 16(3):254-7. PubMed ID: 23981744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions.
    Ke CH; Chung WH; Wen YH; Huang YB; Chuang HY; Tain YL; Wang YL; Wu CC; Hsu CN
    J Rheumatol; 2017 Jun; 44(6):835-843. PubMed ID: 28365572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating real-world data in cost-effectiveness analysis of universal HLA-B*15:02 screening in Malaysia.
    Chong HY; Lim KS; Fong SL; Shabaruddin FH; Dahlui M; Mei Lai PS; Ng CC; Chaiyakunapruk N
    Br J Clin Pharmacol; 2023 Nov; 89(11):3340-3351. PubMed ID: 37294011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population.
    Gonçalo M; Coutinho I; Teixeira V; Gameiro AR; Brites MM; Nunes R; Martinho A
    Br J Dermatol; 2013 Sep; 169(3):660-5. PubMed ID: 23600531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs.
    Park HJ; Kim YJ; Kim DH; Kim J; Park KH; Park JW; Lee JH
    Yonsei Med J; 2016 Jan; 57(1):118-26. PubMed ID: 26632391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is universal HLA-B*15:02 screening a cost-effective option in an ethnically diverse population? A case study of Malaysia.
    Chong HY; Mohamed Z; Tan LL; Wu DBC; Shabaruddin FH; Dahlui M; Apalasamy YD; Snyder SR; Williams MS; Hao J; Cavallari LH; Chaiyakunapruk N
    Br J Dermatol; 2017 Oct; 177(4):1102-1112. PubMed ID: 28346659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.
    Pruis SL; Jeon YK; Pearce F; Thong BY; Aziz MIA
    J Med Econ; 2020 Aug; 23(8):838-847. PubMed ID: 32301360
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of screening for HLA-B*1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States.
    Choi H; Mohit B
    Epilepsia; 2019 Jul; 60(7):1472-1481. PubMed ID: 31158306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic Evaluation of HLA-B*15:02 Genotyping for Asian Australian Patients With Epilepsy.
    Gu Y; Shih STF; Geevasinga N; Chan L; Frew JW; Sebaratnam DF
    JAMA Dermatol; 2024 Jun; 160(6):631-640. PubMed ID: 38717780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Cristallo AF; Schroeder J; Citterio A; Santori G; Ferrioli GM; Rossi U; Bertani G; Cassano S; Gottardi P; Ceschini N; Barocci F; Ribizzi G; Cutrupi V; Cairoli R; Rapisarda V; Pastorello EA; Barocci S
    Int J Immunogenet; 2011 Aug; 38(4):303-9. PubMed ID: 21545408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand.
    Rattanavipapong W; Koopitakkajorn T; Praditsitthikorn N; Mahasirimongkol S; Teerawattananon Y
    Epilepsia; 2013 Sep; 54(9):1628-38. PubMed ID: 23895569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain.
    Kulkantrakorn K; Tassaneeyakul W; Tiamkao S; Jantararoungtong T; Prabmechai N; Vannaprasaht S; Chumworathayi P; Chen P; Sritipsukho P
    Pain Pract; 2012 Mar; 12(3):202-8. PubMed ID: 21676164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.